Back to News
Security News

Spotlight On: Actemra® (tocilizumab) / Tofidence™ (tocilizumab-bavi) / Tyenne® (tocilizumab-aazg) / Avtozma® (tocilizumab-anoh) - April 2026

UnknownApr 17, 2026(23 days ago)

The article discusses challenges to claims in IPRs related to Tocilizumab patents.

Tocilizumab Challenged Claim Types in IPRs: Claims are counted in each IPR, so claims from the same patent challenged in multiple IPRs are counted more than once. Within each IPR, claims are counted only once, whether they are challenged under § 102, § 103, or both.... By: Venable LLP

Related News

Get Personalized Alerts

Track vendors and receive alerts when security incidents affect your supply chain.

What We Monitor

Security Incidents

Data breaches, ransomware, and unauthorized access

Vulnerabilities

CVEs and vendor security advisories

Compliance Updates

Regulatory changes and certification news

Legal News

Privacy laws and enforcement actions

Vendor Directory

Browse our directory of SaaS vendors with security documentation and compliance information.